DNA-Guided immunotherapy trial aims to match drug to tumor

NCT ID NCT04273061

Recruiting now Disease control Sponsor: British Columbia Cancer Agency Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis can help select who benefits most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (TECENTRIQ), an immunotherapy drug given by IV every 3 weeks
What this could lead to: If successful, this could show that analyzing a tumor's DNA can predict which patients will benefit from atezolizumab, leading to more personalized cancer treatment.
What could go wrong: This is an early Phase 2 trial with small groups per cancer type, so results may not apply broadly. Not all participants will respond, and side effects from immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer of unknown primary site digestive system cancer digestive system neoplasm female reproductive organ cancer head and neck cancer Head and Neck Neoplasms lung cancer lung neoplasm malignant urinary system neoplasm Neoplasms, Unknown Primary sarcoma skin cancer skin neoplasm Urogenital Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER GASTROINTESTINAL CANCER GENITOURINARY CANCER GYNECOLOGIC CANCER HEAD AND NECK CANCER LUNG CANCER SARCOMA SKIN CANCER UNKNOWN PRIMARY TUMORS

Contacts and locations

Locations

BC Cancer
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
University Health Network / Princess Margaret Cancer Centre
WITHDRAWN

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.